itacitinib + docetaxel

**Itacitinib + docetaxel** is an investigational combination therapy consisting of itacitinib, a selective Janus kinase 1 (JAK1) inhibitor, and docetaxel, a widely used taxane-class chemotherapeutic agent that promotes microtubule assembly and stability, leading to inhibition of cell division. This combination is being studied for enhanced antineoplastic effects, leveraging targeted inhibition of cytokine signaling along with direct cytotoxicity. Itacitinib is primarily developed by Incyte for hematologic and oncological indications, while docetaxel is broadly used in various cancers. Combination regimens seek to improve efficacy in solid tumors such as non-small cell lung cancer and other advanced malignancies.